Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should all stroke patients receive tissue plasminogen activator therapy, despite mild or improving symptoms?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 184–185 (2006)Cite this article

boxed-textSmith EE et al. (2005) Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 36: 2497–2499

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Caplan L et al. (1997) Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? N Engl J Med 337: 1309–1310

    Article  CAS  Google Scholar 

  2. Hacke W et al. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: 768–774

    Article  Google Scholar 

  3. Barber PA et al. (2001) Why are stroke patients excluded from TPA therapy? Neurology 56: 1015–1020

    Article  CAS  Google Scholar 

  4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581–1588

  5. Lyden PD (2005) Thrombolytic Therapy for Acute Stroke. Totowa: Humana Press

    Book  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the UCSD Stroke Center, Professor of Neurosciences at UCSD School of Medicine and a staff physician at the VA Medical Center San Diego, CA, USA

    Patrick D Lyden

Authors
  1. Patrick D Lyden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick D Lyden.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyden, P. Should all stroke patients receive tissue plasminogen activator therapy, despite mild or improving symptoms?. Nat Rev Cardiol 3, 184–185 (2006). https://doi.org/10.1038/ncpcardio0511

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0511

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing